CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$17.70

30 Nov
2023

-0.350

OPEN

$18.11

-1.94%

HIGH

$18.20

152,218

LOW

$17.63

TARGET
$21.333 20.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 61.9 73.1 xxx
DPS (cps) xxx 5.0 6.5 xxx
EPS Growth xxx 46.6% 18.0% xxx
DPS Growth xxx 25.0% 30.0% xxx
PE Ratio xxx N/A 24.3 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 8.1% 8.9% xxx

Dividend yield today if purchased 3 years ago: 0.24%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.28

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx61.9
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx78.3 M
Book Value Per Share xxxxxxxxxxxxxxx333.2
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx39.08 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx21.09 %
Return on Invested Capital xxxxxxxxxxxxxxx20.97 %
Return on Assets xxxxxxxxxxxxxxx18.04 %
Return on Equity xxxxxxxxxxxxxxx21.09 %
Return on Total Capital xxxxxxxxxxxxxxx27.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx33.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx157 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

16/11/2023

3

Initiation of coverage with Hold

$18.00

1.69%

Ord Minnett has initiated coverage of Clinuvel Pharmaceuticals with an $18 fair value calculation and a Hold rating, suggesting the market is too pessimistic about this biotech's future.

The company's key product, Scenesse, is the only approved treatment for phototoxic reactions specifically associated with erythropoietic protoporphyria (EPP), a rare genetic disease, the analyst explains.

 Current forecasts are for a five-year group CAGR of 13% compared with 19% revenue growth in FY23.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 7.50 cents and EPS of 73.40 cents.
Ord Minnett forecasts a full year FY25 dividend of 9.00 cents and EPS of 88.40 cents.

Morgans

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CUV STOCK CHART

FNArena News on CUV

1
Australian Broker Call *Extra* Edition – Oct 26, 2023

Oct 26 2023 - Daily Market Reports
2
Rudi’s View: Yield Is Back

Oct 18 2023 - Rudi's View
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Australian Broker Call *Extra* Edition – Sep 08, 2023

Sep 08 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 04, 2023

Sep 04 2023 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
2
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
3
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
4
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
5
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
6
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
7
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
8
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
10
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps